ArteraAI

Categories: Healthcare, Data Analysis | Pricing: Pricing unavailable | Official Website ↗

ArteraAI provides AI-powered precision oncology tests that analyze digital pathology and clinical data to personalize cancer treatment.

ArteraAI is a leader in AI-powered precision medicine, utilizing a multi-modal artificial intelligence (MMAI) platform. This platform analyzes digital pathology and clinical data to provide personalized cancer management insights. The technology has been validated in numerous large, randomized phase III clinical trials. ArteraAI has achieved FDA De Novo Authorization for ArteraAI Prostate, an AI-powered digital pathology risk stratification tool regulated as Software as a Medical Device (SaMD). This tool offers therapeutic insights for early-stage prostate cancer and can predict which NCCN Intermediate-risk patients will benefit from ST-ADT with radiation therapy. It is the first AI test recommended in NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer. In addition to prostate cancer, ArteraAI also offers a Breast Cancer Test, which provides 5- and 10-year distant metastasis risk for early-stage breast cancer patients and predicts chemotherapy benefit for certain node-negative patients.

Key Features

AI-powered risk stratification for prostate cancer
Prediction of treatment benefit for prostate cancer patients
5- and 10-year distant metastasis risk for breast cancer
Prediction of chemotherapy benefit for breast cancer patients
Analysis of existing H&E slides without additional staining
Rapid turnaround of results (1-2 days)
Consistent prognostic performance across diverse populations

Pros

FDA De Novo Authorization for prostate cancer test
Recommended in NCCN Clinical Practice Guidelines for Prostate Cancer
Utilizes existing digital pathology slides, no tissue consumption
Provides rapid results for timely treatment decisions
Validated in large, randomized phase III clinical trials
Covered by Medicare and many commercial health plans

Cons

Specific pricing details are not publicly available
Focus primarily on prostate and breast cancer currently
Requires patient specimen to be sent to CLIA lab
Website does not detail specific integrations with EMRs or other systems
No direct patient-facing ordering portal, requires clinician involvement

Use Cases

Personalizing treatment plans for prostate cancer patients
Assessing risk stratification for nonmetastatic prostate cancer
Predicting benefit from specific therapies like ST-ADT for prostate cancer
Determining distant metastasis risk for early-stage breast cancer
Guiding chemotherapy decisions for node-negative breast cancer patients

Best For

Oncologists
Urologists
Radiation oncologists
Pathologists
Patients with prostate cancer
Patients with early-stage breast cancer

Platforms: Web

Watch demo on YouTube ↗

View full ArteraAI profile on Tools-Radar | Browse Healthcare tools | Alternatives to ArteraAI

Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com